STORY CONTINUES BELOW THESE SALTWIRE VIDEOS - CVS Health Corp said on Wednesday it has launched Cordavis, a unit that will work directly with manufacturers to commercialize and co-produce biosimilars for the U.S. market.
The company will also launch biosimilar Hyrimoz with Novartis' Sandoz from next year at a list price that is more than 80% lower to AbbVie's blockbuster arthritis drug Humira.
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Global stock market correction likely before year-end: Reuters pollBy Hari Kishan BENGALURU (Reuters) - Global stock markets are heading for a correction in coming months, though overall they should post marginal gains ...
続きを読む »